About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
Recommencement of ZIRCON Phase III Trial Recruitment in EU
Melbourne (Australia) – 18th June 2020. Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has...
Presentation to Jefferies Virtual Healthcare Conference
Melbourne (Australia) 4th June 2020 - Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at...
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...